Please ensure Javascript is enabled for purposes of website accessibility
top of page

Karyopharm spotlights PhIII results after controversial FDA approval

There are mountain ranges with less jagged curves than Karyopharm’s stock $KPTI.


Over the last year, the biotech has risen and cratered and risen again as a debate over whether its lead drug is safe — or even works — played out in public FDA reviews and advisory committee hearings. But after a skeptical internal review from the agency noted previously undisclosed trial deaths and a solid majority of outside advisors voted to reject the drug, Karyopharm emerged in July with a surprise accelerated approval for selinexor, now called Xpovio.


Comentários


bottom of page